Evolution Biotech, Author at Evolution Biotechnologies - Page 3 of 3
1
archive,paged,author,author-leadbroker,author-1,paged-3,author-paged-3,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Bedford, UK, and Austin, Texas; September 14th 2016 ­Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announces a presentation by its Chief Officer, Dr. David Harper. The presentation, entitled “Bacteriophages as Biological Control Agents” is to be given on Friday 16th September at the conference on “Phage-based Technologies Against Antimicrobial Resistance” organised under the EU FP7 EVOPROG programme, in Stratford-upon-Avon, UK. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s...

Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced that its UK patent application, “Acaricides” (GB1513981.9), relating to biological controls for house dust mites has progressed to the international stage as PCT application PCT/GB2016/052455. The PCT filing incorporates both data from the previous successful feasibility study and also recent findings identifying a biological agent capable of targeting multiple mite species. Dr. David Harper, Chief Officer of Evolution, said “we are delighted to be able to incorporate the recent and exciting findings from our HDM research group, headed by Senior Scientist Dr....

Bedford, UK, and Austin, Texas; July 8th 2016 Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced its sponsorship of the forthcoming EMBO Viruses of Microbes (#EMBOVoM2016) meeting in Liverpool (http://events.embo.org/16-virus-microbe/ ). The company will attend the meeting both to promote its new activities in the area and to recruit staff for its expanded operations. Dr. David Harper, Chief Officer of Evolution, said “I am delighted that the company is supporting this important meeting, and look forward to attending along with other company staff.” About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 / US...

­Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced an important development in its operations, with the establishment of its therapeutic division. This will work to develop the therapeutic use of bacteria-killing viruses, or bacteriophages, an approach known as phage therapy. This is recognised as a highly promising approach to the control of antibiotic-resistant bacterial infections. Dr. David Harper, the founder and Chief Officer of Evolution has unique experience in this area, having previously run the only modern clinical trial to demonstrate the efficacy of the approach, and demonstrated the effectiveness...

Bedford, UK, and Austin, Texas; June 10,  2016 Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced the formation of its US-based subsidiary, Evolution Biotechnologies Inc. of Delaware. The company has been established to support operations at the planned company facility in Austin, Texas. Aaron Gunn, Chief Operating Officer of Evolution, said “This is an important step for the company, and will help facilitate our expansion into the United States.”   About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its...

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the appointment of Dr. Victor Brugman as senior scientist on its dust mite control project. Dr. Brugman will be working with the ARCTEC unit at the London School of Hygiene and Tropical Medicine in London in the early stages of the work, and will be moving to the company’s central facility at Colworth Science Park later in the year. Dr. David Harper, Chief Officer of Evolution, said “This is an important step for the company, I would like to welcome Dr....

Evolution Biotehnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the opening of its office at Colworth Science Park in Bedfordshire. This is intended to keystone the development of the company’s laboratory and other facilities at this location over the next year. The office is managed by Ms. Hayley Styche, who has joined the company in an administrative role. Dr. David Harper, Chief Officer of Evolution, said “This is an important step for the company, and Colworth is the ideal location for our business to develop and grow. Ms. Styche...

Evolution Biotechnologies announces completion of initial funding round and appointment of Chief Operating Officer Evolution Biotehnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the closure of its first funding round, having raised the full sum sought at this time. The investment will support the establishment of the company’s development streams and central corporate facility ahead of further funding rounds. Further announcements on staff appointments and activities are planned for the near future. The company also announced the appointment of Mr. Aaron Gunn to the board and to the post of Chief...

Evolution Biotechnologies founder Dr. David Harper interviewed for the financial website SeekingAlpha Dr. David Harper, the founder of Evolution Biotechnologies(www.evolutionbiotech.com), has been interviewed for the US financial website SeekingAlpha (seekingalpha.com). The interview covered both Dr. Harper’s previous work on bacteriophage therapy and the new technologies being developed by Evolution Biotechnologies. The SeekingAlpha website states: "Today I had the privilege of interviewing Dr. David Harper, who just recently departed as Chief Science Officer of AmpliPhi Biosciences (OTCQB:APHB). Founder of the infectious disease pioneer Biocontrol, which conducted the first human clinical trial of a bacteriophage, Dr. Harper is a member of the Alternatives to...

Evolution Biotechnologies announces filing of its first patent application relating to the development of biological controls for the house dust mite Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the filing of UK patent application GB1513981.9, “Acaricides”, relating to its planned development of biological controls for the house dust mite. The application includes exemplification from the successful feasibility study previously carried out under the direction of Evolution’s Chief Officer, Dr. David Harper. “This is an important step forward for the company, with claims detailing our initial targets and including important...